stars 1 stars 2 stars 3

Amryt Pharma was acquired by Chiesi Farmaceutici S.p.A. (“Chiesi”) April 12, 2023. Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt Pharma's online communities are open to the public. Anything posted to our social networks may be seen and read by everyone. We cannot be responsible for views expressed other than our own. By posting on Amryt Pharma's social media pages, you grant us the right to use or reproduce your content. We welcome questions and commentary, including constructive feedback and differing opinions, but please remember to be both relevant and respectful with what you post. We do not tolerate harassment, abuse, or threats to others. We reserve the right to remove any posts that don’t adhere to our guidelines and to block anyone who violates them repeatedly. Learn more about our community guidelines here: https://amrytpharma.com/social-media-guidelines/

Amryt Pharma Questions

The Amryt Pharma annual revenue was $233.2 million in 2026.

Tanuja Somani is the CMO Quality Manager of Amryt Pharma.

44 people are employed at Amryt Pharma.

The NAICS codes for Amryt Pharma are [325, 62151, 21, 62, 211111, 211, 21111, 6215, 2111, 32, 621].

The SIC codes for Amryt Pharma are [28, 283].

Top Amryt Pharma Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users